Antibody response (geometric mean titre) · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Invasive cervical, vaginal, vulval, anal, or penile cancer · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall systemic events and general symptoms · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Clinical and harms outcomes* · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical and harms outcomes* · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibody response (immunogenicity) · 9‐ to 15‐year‐old females
Two doses of HPV vaccine probably leads to lower antibody response (immunogenicity) compared with three doses of HPV vaccine (moderate certainty).
1 finding from 1 review
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, and vaginal disease · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall systemic events and general symptoms · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 15‐year‐old females
It is very uncertain whether two doses of HPV vaccine changes serious adverse events at up to 5‐year compared with three doses of HPV vaccine (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 15‐year‐old females
Two doses of HPV vaccine showed no clear difference in mortality at up to 5‐year compared with three doses of HPV vaccine (low certainty).
1 finding from 1 review